Page last updated: 2024-10-25

desipramine and Lewy Body Disease

desipramine has been researched along with Lewy Body Disease in 1 studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Lewy Body Disease: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldstein, DS1
Holmes, C1
Kopin, IJ1
Sharabi, Y1

Other Studies

1 other study available for desipramine and Lewy Body Disease

ArticleYear
Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.
    The Journal of clinical investigation, 2011, Volume: 121, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Cytosol; Desipramine; Dopamine; Female; Fluori

2011